Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Elevance Health Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Elevance Health Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The financial performance across the analyzed period is characterized by an initial phase of relative stability followed by a systematic contraction in profitability and efficiency ratios starting in late 2024. While the company maintained consistent margins through the first half of 2024, a sustained downward trajectory is evident across all key profitability metrics through March 2026.
- Profit Margin Analysis
- Gross profit margins remained remarkably stable between 16.79% and 16.92% from March 2022 through June 2024. However, a significant decline began in September 2024, with the margin falling consistently to 14.18% by March 2026. This compression suggests an increase in the direct cost of services or a reduction in pricing power.
- Operating and net profit margins mirrored this downward trend. Operating margins, which hovered around 5% in 2022, experienced a gradual decline to 4.47% by December 2023, a brief recovery to 4.76% in June 2024, and a subsequent sharp drop to 2.79% by March 2026. Net profit margins followed a similar path, decreasing from a peak of 4.37% in March 2022 to a period low of 2.64% by the end of the analyzed timeframe.
- Return on Investment Ratios
- Return on Equity (ROE) demonstrates a clear erosion of shareholder value generation. Starting at 17.36% in March 2022, the ROE remained above 15% until September 2024. From that point, a steady decline occurred, reaching 11.94% by March 2026, representing a substantial reduction in equity efficiency.
- Return on Assets (ROA) reflects a parallel decline in asset utilization efficiency. The ROA shifted from a range of 5.86% to 6.21% in 2022 to a low of 4.17% by March 2026. The consistent drop in both ROE and ROA indicates that the decline in profitability is not being offset by changes in leverage or asset turnover.
In summary, the profitability profile shifted from a state of equilibrium to one of contraction. The synchronization of the decline across gross, operating, and net margins, coupled with falling return ratios, indicates a broader systemic pressure on the company's ability to maintain its historical profit levels and operational efficiency.
Return on Sales
Return on Investment
Gross Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||
| Operating revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Gross profit margin = 100
× (Gross profitQ1 2026
+ Gross profitQ4 2025
+ Gross profitQ3 2025
+ Gross profitQ2 2025)
÷ (Operating revenueQ1 2026
+ Operating revenueQ4 2025
+ Operating revenueQ3 2025
+ Operating revenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analysis of profitability indicators reveals a distinct transition from a period of operational stability to a sustained contraction in gross profit margins, occurring despite a consistent upward trajectory in overall operating revenue.
- Gross Profit Margin Stability (March 2022 – June 2024)
- From March 31, 2022, through June 30, 2024, the gross profit margin remained remarkably stable, oscillating within a narrow range between 16.79% and 17.16%. The margin reached its peak of 17.16% in June 2024, reflecting a period of consistent cost management relative to revenue growth.
- Margin Erosion and Contraction (September 2024 – March 2026)
- A significant and steady downward trend in the gross profit margin is observed beginning in the third quarter of 2024. The margin declined from 16.62% in September 2024 to 14.18% by March 31, 2026. This continuous decline suggests that the direct costs of services or goods increased at a disproportionately higher rate than the revenue generated during this period.
- Revenue and Profitability Divergence
- Operating revenue demonstrated strong growth, increasing from 37,886 million US dollars in March 2022 to 49,494 million US dollars by March 31, 2026. However, a divergence is evident between top-line growth and profitability efficiency. While the scale of operations expanded, the gross profit margin experienced a persistent decline in the final six quarters, indicating that increased revenue volume did not yield the same proportional profit margins observed in earlier periods.
Operating Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Operating income | |||||||||||||||||||||||
| Operating revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Operating profit margin = 100
× (Operating incomeQ1 2026
+ Operating incomeQ4 2025
+ Operating incomeQ3 2025
+ Operating incomeQ2 2025)
÷ (Operating revenueQ1 2026
+ Operating revenueQ4 2025
+ Operating revenueQ3 2025
+ Operating revenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analyzed period is characterized by a sustained contraction in operating profitability despite a consistent increase in operating revenue. The operating profit margin exhibits a long-term downward trajectory, declining from 5.10% in March 2022 to 2.79% by March 2026.
- Revenue and Profitability Divergence
- Operating revenue grew from 37,886 million US dollars in March 2022 to 49,494 million US dollars in March 2026. However, this top-line growth failed to translate into increased operating income, which decreased from 2,318 million US dollars to 1,974 million US dollars over the same timeframe. This divergence indicates that operating expenses grew at a rate that significantly outpaced revenue gains.
- Operating Profit Margin Erosion
- A consistent erosion of the operating profit margin is observed. The margin remained relatively stable near 5% during 2022, but entered a phase of steady decline starting in 2023. The contraction accelerated in the final two years of the period, moving from 4.64% in March 2024 to 2.79% in March 2026, reflecting a substantial reduction in operational efficiency.
- Cyclical Performance Volatility
- The data reveals a recurring quarterly pattern where operating income and margins reach their annual troughs in the fourth quarter (December). This seasonal volatility has intensified over time; the December operating income fell from 1,121 million US dollars in 2022 to 145 million US dollars in 2025. This increasing year-end weakness has become a primary driver of the overall margin decline.
Net Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Shareholders’ net income | |||||||||||||||||||||||
| Operating revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Net profit margin = 100
× (Shareholders’ net incomeQ1 2026
+ Shareholders’ net incomeQ4 2025
+ Shareholders’ net incomeQ3 2025
+ Shareholders’ net incomeQ2 2025)
÷ (Operating revenueQ1 2026
+ Operating revenueQ4 2025
+ Operating revenueQ3 2025
+ Operating revenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
An analysis of the financial performance from March 31, 2022, to March 31, 2026, reveals a divergence between top-line growth and bottom-line efficiency. While operating revenue has demonstrated a consistent upward trajectory, the net profit margin has undergone a sustained period of compression.
- Operating Revenue Trends
- Operating revenue grew steadily from 37,886 million USD in March 2022 to 49,494 million USD by March 2026. The growth pattern is characterized by a gradual climb, successfully crossing the 40,000 million USD threshold in early 2023 and maintaining a range between 48,000 and 50,000 million USD throughout 2025 and early 2026.
- Net Profit Margin Compression
- A clear downward trend is observed in the net profit margin over the analyzed period. Starting at a peak of 4.37% in March 2022, the margin declined to 2.64% by March 2026. This erosion indicates that operating expenses or other non-operating costs have increased at a faster rate than revenue growth, reducing the percentage of each dollar of revenue that translates into net profit.
- Net Income Volatility and Seasonality
- Shareholders' net income exhibits significant quarterly volatility with a pronounced seasonal pattern. A recurring decline in net income is observed every fourth quarter, with lows recorded in December 2022 (949 million USD), December 2023 (856 million USD), December 2024 (418 million USD), and December 2025 (547 million USD). Conversely, peak earnings typically occur in the first or second quarters of the year, such as the highs seen in March and June 2024.
- Profitability Correlation
- The relationship between expanding revenue and shrinking margins suggests a diminishing return on scale. Despite the increase in total operating revenue by approximately 30% over the period, the net profit margin decreased by nearly 40% relative to its starting point, signaling a reduction in overall operational profitability.
Return on Equity (ROE)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Shareholders’ net income | |||||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
ROE = 100
× (Shareholders’ net incomeQ1 2026
+ Shareholders’ net incomeQ4 2025
+ Shareholders’ net incomeQ3 2025
+ Shareholders’ net incomeQ2 2025)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
An analysis of profitability metrics reveals a sustained downward trend in Return on Equity (ROE) over the period from March 2022 to March 2026. While the ROE remained relatively stable and above 16% throughout 2022, a gradual and consistent erosion of this ratio is observed in subsequent years, concluding at 11.94% in the first quarter of 2026.
- Return on Equity (ROE) Trajectory
- The ROE exhibited a clear decline, falling from a high of 17.36% in March 2022 to 11.94% by March 2026. The decline was most pronounced starting in 2024, where the ratio shifted from a range of 14% to 15% down to approximately 12% by 2025 and early 2026. This indicates a reduction in the efficiency of generating profit relative to the invested shareholders' equity.
- Shareholders' Equity Expansion
- There is a general upward trend in shareholders' equity, which grew from 35,975 million USD in March 2022 to 43,902 million USD by March 2026. This expansion of the equity base has contributed to the compression of the ROE, as the growth in the denominator has outpaced the growth in net income over the long term.
- Net Income Patterns
- Net income displays significant quarterly volatility and a recurring seasonal pattern, with sharp declines typically occurring in the December quarters. For instance, net income dropped to 856 million USD in December 2023 and further to 418 million USD in December 2024. Although the company experienced periodic recoveries in the first and second quarters of each year, these gains were insufficient to offset the overall impact of a larger equity base on the ROE calculation.
Return on Assets (ROA)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Shareholders’ net income | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
ROA = 100
× (Shareholders’ net incomeQ1 2026
+ Shareholders’ net incomeQ4 2025
+ Shareholders’ net incomeQ3 2025
+ Shareholders’ net incomeQ2 2025)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
An analysis of profitability metrics reveals a consistent long-term decline in the Return on Assets (ROA) from March 31, 2022, through March 31, 2026. The ROA decreased from a peak of 6.21% to a period low of 4.17%, indicating a reduction in the efficiency with which assets are utilized to generate net income.
- Asset Base Expansion
- Total assets demonstrated a steady upward trajectory, growing from 100,486 million USD in March 2022 to 125,827 million USD by March 2026. This continuous expansion of the balance sheet suggests an increase in the total resource investment over the analyzed period.
- Net Income Volatility
- Shareholders' net income exhibited significant quarterly fluctuations rather than a linear trend. Notable peaks occurred in March and June of 2024 and 2025, while sharp contractions were observed in the fourth quarters of 2024 and 2025, with values falling to 418 million USD and 547 million USD, respectively. These cyclical dips contributed to the overall instability of the profitability ratio.
- ROA Compression Patterns
- The downward trend in ROA is a result of the widening gap between the growing asset base and the volatile net income. Because total assets increased consistently while net income failed to sustain a proportional growth rate, the return per unit of asset declined. A period of relative stability was observed between March 2023 and June 2024, where ROA hovered between 5.50% and 5.92%, followed by a more pronounced decline starting in late 2024 and continuing through March 2026.